H3.3 CTL peptides and uses thereof
US-10849965-B2 · Dec 1, 2020 · US
H3.3 CTL peptides and uses thereof
US11925679B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11925679-B2 |
| Application number | US-202017077806-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2020 |
| Priority date | May 5, 2015 |
| Publication date | Mar 12, 2024 |
| Grant date | Mar 12, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide sequence comprising a T-cell receptor (TCR) or a fragment thereof, wherein the TCR or the fragment thereof binds to a peptide/major histocompatibility complex (WIC) complex, and wherein the peptide in the peptide/WIC complex consists of 10 to 12 amino acids and comprises (R/A)MSAP(S/A)TGGV (SEQ ID NO:1). 2. The polypeptide sequence according to claim 1 , wherein the peptide consists of RMSAPSTGGV (SEQ ID NO: 2). 3. The polypeptide sequence according to claim 1 , wherein the arginine (R) in SEQ ID NO:1 is citrullinated. 4. The polypeptide sequence according to claim 1 , wherein the TCR or the fragment thereof comprises one or more heterologous sequences.
Assignees
Inventors
Classifications
Cancer antigens · CPC title
T-cell receptors [TCR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
Brain; Nervous system · CPC title
characterized by the route of administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11925679B2 cover?
- Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification G01N33/505. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).